chemieunternehmen.com

The Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute and Evotec AG today announced a research collaboration aimed at discovering and commercialising novel cancer treatments based on epigenetic drug mechanisms. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/dana-farbers-belfer-institute-for-applied-cancer-science-and-evotec-establish-collaboration-in-oncology-5131

Evotec AG today announced that Evotec (US) Inc. has executed a multi-year lease on a facility specifically designed to expand the offering of its Compound Management Services on the East Coast of the United States. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-compound-management-capability-to-east-coast-of-the-united-states-5129

Evotec AG today announced an auspicious step in research from Harvard University. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/new-hormone-to-treat-diabetes-published-in-cell-5127

Evotec AG today announced that it has extended its drug discovery alliance with Genentech, a member of the Roche Group, for three additional years. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-extends-drug-discovery-alliance-with-genentech-5125

Evotec AG today reported financial results and corporate updates for the fiscal year ended 31 December 2012. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/forward-step-by-step-with-action-plan-2016—continued-revenue-growth—significant-pipeline-progress-5123

Evotec AG today announced that Dr Werner Lanthaler, Chief Executive Officer of Evotec, will resume his role as Chief Executive Officer of the Company with immediate effect after a period of leave due to health reasons. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/corporate-update-5119

Evotec AG today announced that a compound identified and optimised in a research collaboration with Ono Pharmaceutical Co., Ltd. has been nominated to enter pre-clinical development, leading to the payment of an agreed milestone. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-milestone-in-drug-discovery-collaboration-with-ono-pharmaceutical-co-ltd-5117

Evotec AG today announced that it has entered into a strategic partnership with Yale University. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-yale-university-form-open-innovation-alliance-5115

Evotec AG today announced that it has expanded the scope of its collaboration with MedImmune, the global biologics arm of AstraZeneca, after hitting a key milestone. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-collaboration-with-medimmune-receives-milestone-payment-5111